Mocravimod
As of the edition of 20 October 2026, Mocravimod is a small molecule: in active development; acts on S1PR1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 4, 1 stopped early
- Disease areas
- Blood and lymph; Cancer; Digestive system; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| S1PR1 | Sphingosine 1-phosphate receptor 1 | P21453 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 2 | 1 | 0 | 1 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 4 |